Savara Inc. develops therapies for rare respiratory diseases, with a lead program in molgramostim inhalation solution, conditionally named MOLBREEVI, for autoimmune pulmonary alveolar proteinosis. Molgramostim is a recombinant human GM-CSF delivered through an investigational eFlow Nebulizer System developed for inhalation of the large-molecule therapy.
Recurring company developments include clinical data from the IMPALA-2 program, regulatory submissions and agency-review updates in the U.S., Europe and the U.K., financial results, financing arrangements, equity inducement grants and investor conference participation. Savara's updates also note that MOLBREEVI is not approved in any indication.
Savara, a clinical-stage biopharmaceutical company specializing in rare respiratory diseases, will host a conference call and webcast on June 26, 2024, at 8:00am ET to discuss the top line results from its pivotal Phase 3 IMPALA-2 trial. This trial assesses the safety and efficacy of molgramostim, an inhaled GM-CSF, in treating autoimmune pulmonary alveolar proteinosis (aPAP). A press release detailing these results will be issued at 6:30am ET on the same day, prior to the call. Stakeholders can access the live webcast through Savara's website or by phone registration, with a replay available for 90 days.
Savara, a clinical stage biopharmaceutical company focusing on rare respiratory diseases, announced its participation in the Jefferies Global Healthcare Conference. The management team will engage in a fireside chat scheduled for June 5, 2024, at 7:00am PT/10:00am ET. The event will be live-streamed on Savara's website and will remain accessible for 90 days. This conference is a significant platform for industry exposure, potentially impacting SVRA stock performance.
Savara (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented significant data at the American Thoracic Society (ATS) 2024 International Conference. The event, taking place from May 17-22, 2024, in San Diego, CA, featured two important posters.
Poster Board 701, sponsored by Savara, detailed a cohort study revealing that pulmonary alveolar proteinosis (PAP) patients face a substantial healthcare burden. This includes a 4-fold increase in hospital admissions and costs compared to non-PAP controls.
Poster Board 702, presented by Trillium Health , showcased a novel laboratory test for diagnosing autoimmune pulmonary alveolar proteinosis (aPAP) with 100% clinical accuracy. This test detects GM-CSF antibodies in human serum, offering a precise and sensitive diagnostic tool.
Savara has announced inducement awards for a new employee hired on May 14, 2024. The awards include options to purchase 15,000 shares of common stock and 2,500 restricted stock units (RSUs). The options, priced at $4.81 per share, align with the closing trading price on the grant date and have a 10-year term. The options vest quarterly over four years, while the RSUs vest in full after two years. These grants are made under Savara's 2021 Inducement Equity Incentive Plan according to NASDAQ Rule 5635(c)(4).
Savara Inc. (Nasdaq: SVRA) reported their first-quarter financial results for 2024, showcasing a net loss of $20.3 million compared to $10.6 million in 2023. The company remains focused on the Phase 3 IMPALA-2 trial evaluating molgramostim for autoimmune Pulmonary Alveolar Proteinosis, with top-line results expected by 2Q 2024. Savara anticipates submitting a Biologics License Application in 1H 2025 and is well-capitalized with $143 million in cash into 2026.
Savara Inc. (SVRA) will be presenting at the Citizens JMP Life Sciences Conference, with a live webcast available on their website. The event is scheduled for May 14, 2024, at 6:00am PT/9:00am ET, focusing on rare respiratory diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.